Trial record 2 of 4 for:    ALVINA

Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by Children's Research Institute.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Children's Research Institute
ClinicalTrials.gov Identifier:
NCT01587781
First received: April 26, 2012
Last updated: May 10, 2012
Last verified: May 2012
  Purpose

This study is about a drug called enoxaparin which is used to prevent or treat blood clots. There are no studies about the use of this drug in obese adolescents and yet the investigators use it to prevent clots when they have surgery at Children's National for weight loss. The investigators hypothesis is that the obesity leads to increased kidney size and faster drug clearance. Therefore the investigators think they might be underdosing these adolescents. This study will check the drug levels at different points after the drug dose to see whether the investigators are achieving the expected levels for prevention of clots.


Condition
Focus of Study: Pharmacokinetics of Enoxaparin in Obese Children

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery

Resource links provided by NLM:


Further study details as provided by Children's Research Institute:

Estimated Enrollment: 12
Study Start Date: November 2011
Estimated Study Completion Date: May 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Detailed Description:

Enoxaparin is the drug of choice for prevention and treatment of venous thromboembolism (VTE) in children and adults. A major concern with any antithrombotic therapy is an increased risk of hemorrhage. There are not many concrete data published for enoxaparin use in children and adolescents, and absolutely no guidance is available for (morbidly) obese children and adolescents as they are not included in clinical trials during the clinical phases of drug development. Physicians often find themselves puzzled when selecting a dose for obese children. This study aims to find the optimal way to dose enoxaparin in (morbidly) obese children and adolescents that will result in a safe and effective use of this drug as prophylaxis during bariatric surgery.

The optimum therapeutic/preventive dose of a drug depends on its pharmacokinetic and pharmacodynamic properties. Both these processes can be affected by body composition and the physiological changes that occur in obese children. Obesity not only increases the total fat amount, but also the lean body mass. However, the percentage of fat tissue increases more than the lean body mass. Obesity as a disease state is also associated with changes in plasma protein constituents, decreases in tissue perfusion; and increases in adipose tissue mass, lean body mass, cardiac output, and splanchnic blood flow, as compared with normal-weight individuals.

High BMI is believed be an independent risk factor for VTE. Therefore, obese adolescents are also being prescribed prophylactic doses of enoxaparin in situations where there is risk of VTE. The 2008 recommended guidelines by the American College of Chest Physicians does not mention any type of dosing considerations of anticoagulants in obese children. However, it states that higher than usual doses be used in adult patients undergoing bariatric surgery. The use of enoxaparin is not approved for children but is being used widely for the prophylaxis and treatment of VTE in a wide variety of settings in children of all age groups. There are very limited number of studies that involve enoxaparin use in children. Out of these most of the data are available for the use of enoxaparin for the treatment of VTE and not prophylaxis of VTE.

Studies have shown several age related physiologic differences between pediatric and adult patients. Neonates exhibit an accelerated clearance rate and a larger volume of distribution as compared with adults. Children treated for malignancy required higher doses compared to adults. Pharmacokinetic/pharmacodynamic studies that have included children do not provide specific data on different age groups. Further more, the sample size is very small and mostly involve patients that were treated for VTE or thrombophilia. There is no information specifying dosing for prophylactic therapy.

  Eligibility

Ages Eligible for Study:   12 Years to 20 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

A total of 12 patients will be enrolled. The population for this study will include both male and female adolescent patients from all ethnic backgrounds with BMI greater than or equal to 95 percentile. Each patient will receive enoxaparin SC q 12 hours. The blood samples for the study would be taken prior to the second dose.

Criteria

Inclusion Criteria:

  1. The research participant will be a CNMC patient admitted for bariatric surgery.
  2. The age ranges will be between 12 and 20.
  3. All racial and ethnic groups will be included.
  4. The BMI will be calculated using height and weight and will include greater than or equal to 95th percentile. At our bariatric center the minimum BMI is 35 to qualify for surgical intervention for weight loss. In other words, all patients having bariatric surgery will be eligible for inclusion.
  5. Informed consent and assent will be obtained prior to each investigation from the patients' parents and when legally appropriate from the patient.

Exclusion Criteria:

  1. This is a non-interventional study and patients would be routinely screened for history of bleeding disorders or at risk of bleeding as a part of standard complete history and exam. As a standard, patients receiving platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone would be closely monitored.
  2. Any patient with prior dosing with enoxaparin or any other anticoagulant within the past 24 hours would be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01587781

Contacts
Contact: Alvina Mushtaq, MD 202-476-4545 amushtaq@childrensnational.org
Contact: Elaine Williams, RN, MSN 202-476-2455 ewilliams@cnmc.org

Locations
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Alvina Mushtaq, MD    2020-476-4545    amushtaq@cnmc.org   
Contact: Janelle Vaughns, MD    2020-476-8776    JVaughns@cnmc.org   
Principal Investigator: John van den Anker, MD PhD         
Principal Investigator: Janelle Vaughns, MD         
Sub-Investigator: Alvina Mushtaq, MD         
Sub-Investigator: Evan Nadler, MD         
Sub-Investigator: Elaine Williams, RN MSN         
Sub-Investigator: Victoria Ziesenitz, MD         
Sub-Investigator: Nicole Verdun, MD         
Sponsors and Collaborators
Children's Research Institute
  More Information

No publications provided

Responsible Party: Children's Research Institute
ClinicalTrials.gov Identifier: NCT01587781     History of Changes
Other Study ID Numbers: 1824
Study First Received: April 26, 2012
Last Updated: May 10, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Research Institute:
Pharmacokinetics of enoxaparin

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Enoxaparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on August 28, 2014